{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:29:11Z","timestamp":1793316551415,"version":"4.5.0"},"reference-count":191,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010023","name":"Natural Science Research of Jiangsu Higher Education Institutions of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010023","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972719"],"award-info":[{"award-number":["81972719"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82304535"],"award-info":[{"award-number":["82304535"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273207"],"award-info":[{"award-number":["82273207"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82003164"],"award-info":[{"award-number":["82003164"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20220671"],"award-info":[{"award-number":["BK20220671"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20210910"],"award-info":[{"award-number":["BK20210910"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20201012"],"award-info":[{"award-number":["BK20201012"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20210913"],"award-info":[{"award-number":["BK20210913"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.bcp.2025.116762","type":"journal-article","created":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T11:55:52Z","timestamp":1737374152000},"page":"116762","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["LILRB4 as a novel immunotherapeutic target for multiple diseases"],"prefix":"10.1016","volume":"233","author":[{"given":"Xu","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhang","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhangchun","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junnian","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.bcp.2025.116762_b0005","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/BS9.0000000000000109","article-title":"LILRB4, an immune checkpoint on myeloid cells","volume":"4","author":"Yang","year":"2022","journal-title":"Blood Sci"},{"issue":"8\u20139","key":"10.1016\/j.bcp.2025.116762_b0010","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s002510000183","article-title":"Genomic organization of the human leukocyte immunoglobulin-like receptors within the leukocyte receptor complex on chromosome 19q13.4","volume":"51","author":"Liu","year":"2000","journal-title":"Immunogenetics"},{"issue":"2","key":"10.1016\/j.bcp.2025.116762_b0015","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.pep.2005.11.020","article-title":"Expression, purification, and refolding of the myeloid inhibitory receptor leukocyte immunoglobulin-like receptor-5 for structural and ligand identification studies","volume":"47","author":"Garner","year":"2006","journal-title":"Protein Expr Purif"},{"issue":"1","key":"10.1016\/j.bcp.2025.116762_b0020","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/15384101.2015.1121324","article-title":"Inhibitory leukocyte immunoglobulin-like receptors: Immune checkpoint proteins and tumor sustaining factors","volume":"15","author":"Kang","year":"2016","journal-title":"Cell Cycle"},{"key":"10.1016\/j.bcp.2025.116762_b0025","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1282874","article-title":"Human leukocyte immunoglobulin-like receptors in health and disease","volume":"14","author":"Redondo-Garcia","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.bcp.2025.116762_b0030","doi-asserted-by":"crossref","first-page":"857","DOI":"10.3389\/fimmu.2020.00857","article-title":"Leukocyte Immunoglobulin-Like Receptors (LILRs) on Human Neutrophils: Modulators of Infection and Immunity","volume":"11","author":"Lewis Marffy","year":"2020","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.bcp.2025.116762_b0035","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1399-0039.1997.tb02802.x","article-title":"The killer cell inhibitory receptor genomic region on human chromosome 19q13.4","volume":"49","author":"Dupont","year":"1997","journal-title":"Tissue Antigens"},{"issue":"4","key":"10.1016\/j.bcp.2025.116762_b0040","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1177\/1753425917699465","article-title":"A dual positive and negative regulation of monocyte activation by leukocyte Ig-like receptor B4 depends on the position of the tyrosine residues in its ITIMs","volume":"23","author":"Park","year":"2017","journal-title":"Innate Immun"},{"issue":"3","key":"10.1016\/j.bcp.2025.116762_b0045","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/s41423-019-0321-2","article-title":"LILRB4 ITIMs mediate the T cell suppression and infiltration of acute myeloid leukemia cells","volume":"17","author":"Li","year":"2020","journal-title":"Cell Mol Immunol"},{"issue":"12","key":"10.1016\/j.bcp.2025.116762_b0050","doi-asserted-by":"crossref","first-page":"5647","DOI":"10.1172\/JCI97570","article-title":"Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunity","volume":"128","author":"Chen","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bcp.2025.116762_b0055","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1240275","article-title":"Perspectives of targeting LILRB1 in innate and adaptive immune checkpoint therapy of cancer","volume":"14","author":"Zeller","year":"2023","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.bcp.2025.116762_b0060","article-title":"The Leukocyte Immunoglobulin-Like Receptor Family Member LILRB5 Binds to HLA-Class I Heavy Chains","volume":"10","author":"Zhang","year":"2015","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.bcp.2025.116762_b0065","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1158\/2326-6066.CIR-23-0496","article-title":"LILRB3 Supports Immunosuppressive Activity of Myeloid Cells and Tumor Development","volume":"12","author":"Huang","year":"2024","journal-title":"Cancer Immunol Res"},{"issue":"16\u201318","key":"10.1016\/j.bcp.2025.116762_b0070","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0161-5890(02)00079-2","article-title":"Inhibition of anaphylactic inflammation by the gp49B1 receptor on mast cells","volume":"38","author":"Katz","year":"2002","journal-title":"Mol Immunol"},{"issue":"10","key":"10.1016\/j.bcp.2025.116762_b0075","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1084\/jem.185.10.1743","article-title":"A novel inhibitory receptor (ILT3) expressed on monocytes, macrophages, and dendritic cells involved in antigen processing","volume":"185","author":"Cella","year":"1997","journal-title":"J Exp Med"},{"issue":"8","key":"10.1016\/j.bcp.2025.116762_b0080","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.4049\/jimmunol.170.8.4095","article-title":"The gp49B1 inhibitory receptor regulates the IFN-gamma responses of T cells and NK cells","volume":"170","author":"Gu","year":"2003","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.bcp.2025.116762_b0085","doi-asserted-by":"crossref","first-page":"145","DOI":"10.4049\/jimmunol.0803277","article-title":"Tryptophan deprivation induces inhibitory receptors ILT3 and ILT4 on dendritic cells favoring the induction of human CD4+CD25+ Foxp3+ T regulatory cells","volume":"183","author":"Brenk","year":"2009","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.bcp.2025.116762_b0090","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1002\/eji.200324593","article-title":"The rat orthologue to the inhibitory receptor gp49B is expressed by neutrophils and monocytes, but not by NK cells or mast cells","volume":"35","author":"Bryceson","year":"2005","journal-title":"Eur J Immunol"},{"issue":"10","key":"10.1016\/j.bcp.2025.116762_b0095","doi-asserted-by":"crossref","first-page":"5215","DOI":"10.4049\/jimmunol.164.10.5215","article-title":"Inducible expression of the gp49B inhibitory receptor on NK cells","volume":"164","author":"Wang","year":"2000","journal-title":"J Immunol"},{"issue":"6","key":"10.1016\/j.bcp.2025.116762_b0100","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/ng.2653","article-title":"The Genotype-Tissue Expression (GTEx) project","volume":"45","author":"G.T. Consortium","year":"2013","journal-title":"Nat Genet"},{"issue":"12","key":"10.1016\/j.bcp.2025.116762_b0105","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/s41576-020-00296-7","article-title":"Reaching completion for GTEx","volume":"21","author":"Burgess","year":"2020","journal-title":"Nat Rev Genet"},{"issue":"6235","key":"10.1016\/j.bcp.2025.116762_b0110","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1126\/science.1262110","article-title":"Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans","volume":"348","author":"G.T. Consortium","year":"2015","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.bcp.2025.116762_b0115","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/pro.3307","article-title":"The human protein atlas: A spatial map of the human proteome","volume":"27","author":"Thul","year":"2018","journal-title":"Protein Sci"},{"issue":"1","key":"10.1016\/j.bcp.2025.116762_b0120","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/pro.3987","article-title":"The Human Protein Atlas-Spatial localization of the human proteome in health and disease","volume":"30","author":"Digre","year":"2021","journal-title":"Protein Sci"},{"issue":"7728","key":"10.1016\/j.bcp.2025.116762_b0125","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/s41586-018-0615-z","article-title":"LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration","volume":"562","author":"Deng","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2025.116762_b0130","doi-asserted-by":"crossref","unstructured":"Z. Xu, C.C. Chang, M. Li, Q.Y. Zhang, E.M. Vasilescu, V. D'Agati, et al., ILT3.Fc-CD166 Interaction Induces Inactivation of p70 S6 Kinase and Inhibits Tumor Cell Growth, J Immunol 200(3) (2018) 1207-1219.","DOI":"10.4049\/jimmunol.1700553"},{"key":"10.1016\/j.bcp.2025.116762_b0135","doi-asserted-by":"crossref","unstructured":"E. Verschueren, B. Husain, K. Yuen, Y. Sun, S. Paduchuri, Y. Senbabaoglu, et al., The Immunoglobulin Superfamily Receptome Defines Cancer-Relevant Networks Associated with Clinical Outcome, Cell 182(2) (2020) 329-344 e19.","DOI":"10.1016\/j.cell.2020.06.007"},{"issue":"3","key":"10.1016\/j.bcp.2025.116762_b0140","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/intimm\/dxac051","article-title":"Fibronectin-LILRB4\/gp49B interaction negatively regulates osteoclastogenesis through inhibition of RANKL-induced TRAF6\/TAK1\/NF-kB\/MAPK signaling","volume":"35","author":"Su","year":"2023","journal-title":"Int Immunol"},{"issue":"1","key":"10.1016\/j.bcp.2025.116762_b0145","article-title":"Discovery of galectin-8 as an LILRB4 ligand driving M-MDSCs defines a class of antibodies to fight solid tumors","volume":"5","author":"Wang","year":"2024","journal-title":"Cell Rep Med"},{"issue":"3","key":"10.1016\/j.bcp.2025.116762_b0150","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a006312","article-title":"Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease","volume":"2","author":"Holtzman","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"20","key":"10.1016\/j.bcp.2025.116762_b0155","doi-asserted-by":"crossref","first-page":"18013","DOI":"10.1074\/jbc.M111.221028","article-title":"Crystal structure of leukocyte Ig-like receptor LILRB4 (ILT3\/LIR-5\/CD85k): a myeloid inhibitory receptor involved in immune tolerance","volume":"286","author":"Cheng","year":"2011","journal-title":"J Biol Chem"},{"issue":"8","key":"10.1016\/j.bcp.2025.116762_b0160","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1158\/2326-6066.CIR-19-0036","article-title":"Disrupting LILRB4\/APOE Interaction by an Efficacious Humanized Antibody Reverses T-cell Suppression and Blocks AML Development","volume":"7","author":"Gui","year":"2019","journal-title":"Cancer Immunol Res"},{"issue":"8","key":"10.1016\/j.bcp.2025.116762_b0165","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1093\/intimm\/dxac023","article-title":"Myeloid immune checkpoint ILT3\/LILRB4\/gp49B can co-tether fibronectin with integrin on macrophages","volume":"34","author":"Itoi","year":"2022","journal-title":"Int Immunol"},{"issue":"7","key":"10.1016\/j.bcp.2025.116762_b0170","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/intimm\/dxad012","article-title":"Fibronectin on target cells attenuates natural cytotoxicity of NK cells via myeloid immune checkpoint ILT3\/LILRB4\/gp49B","volume":"35","author":"Itagaki","year":"2023","journal-title":"Int Immunol"},{"issue":"7","key":"10.1016\/j.bcp.2025.116762_b0175","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.4049\/jimmunol.1102899","article-title":"Downregulation of inflammatory microRNAs by Ig-like transcript 3 is essential for the differentiation of human CD8(+) T suppressor cells","volume":"188","author":"Chang","year":"2012","journal-title":"J Immunol"},{"issue":"10","key":"10.1016\/j.bcp.2025.116762_b0180","doi-asserted-by":"crossref","first-page":"5714","DOI":"10.4049\/jimmunol.1001732","article-title":"BCL6 is required for differentiation of Ig-like transcript 3-Fc-induced CD8+ T suppressor cells","volume":"185","author":"Chang","year":"2010","journal-title":"J Immunol"},{"issue":"11","key":"10.1016\/j.bcp.2025.116762_b0185","doi-asserted-by":"crossref","first-page":"7432","DOI":"10.4049\/jimmunol.178.11.7432","article-title":"Soluble Ig-like transcript 3 inhibits tumor allograft rejection in humanized SCID mice and T cell responses in cancer patients","volume":"178","author":"Suciu-Foca","year":"2007","journal-title":"J Immunol"},{"issue":"10","key":"10.1016\/j.bcp.2025.116762_b0190","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1182\/blood-2005-05-2044","article-title":"Expression of the inhibitory receptor ILT3 on dendritic cells is dispensable for induction of CD4+Foxp3+ regulatory T cells by 1,25-dihydroxyvitamin D3","volume":"106","author":"Penna","year":"2005","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bcp.2025.116762_b0195","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/87749","article-title":"gp49B1-alpha(v)beta3 interaction inhibits antigen-induced mast cell activation","volume":"2","author":"Castells","year":"2001","journal-title":"Nat Immunol"},{"issue":"9","key":"10.1016\/j.bcp.2025.116762_b0200","doi-asserted-by":"crossref","first-page":"5791","DOI":"10.1074\/jbc.274.9.5791","article-title":"gp49B1 inhibits IgE-initiated mast cell activation through both immunoreceptor tyrosine-based inhibitory motifs, recruitment of src homology 2 domain-containing phosphatase-1, and suppression of early and late calcium mobilization","volume":"274","author":"Lu-Kuo","year":"1999","journal-title":"J Biol Chem"},{"issue":"11","key":"10.1016\/j.bcp.2025.116762_b0205","doi-asserted-by":"crossref","first-page":"8393","DOI":"10.1016\/S0021-9258(17)37207-1","article-title":"Cloning of the gp49B gene of the immunoglobulin superfamily and demonstration that one of its two products is an early-expressed mast cell surface protein originally described as gp49","volume":"269","author":"Castells","year":"1994","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.bcp.2025.116762_b0210","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.4049\/jimmunol.162.3.1318","article-title":"Specificity of the SH2 domains of SHP-1 in the interaction with the immunoreceptor tyrosine-based inhibitory motif-bearing receptor gp49B","volume":"162","author":"Wang","year":"1999","journal-title":"J Immunol"},{"issue":"8","key":"10.1016\/j.bcp.2025.116762_b0215","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1002\/eji.200323978","article-title":"gp49B1 suppresses stem cell factor-induced mast cell activation-secretion and attendant inflammation in vivo","volume":"33","author":"Feldweg","year":"2003","journal-title":"Eur J Immunol"},{"issue":"1","key":"10.1016\/j.bcp.2025.116762_b0220","first-page":"16","article-title":"Leukocyte immunoglobulin-like receptor subfamily B: therapeutic targets in cancer","volume":"4","author":"Deng","year":"2021","journal-title":"Antib Ther"},{"issue":"1","key":"10.1016\/j.bcp.2025.116762_b0225","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s12943-022-01663-0","article-title":"The journey of CAR-T therapy in hematological malignancies","volume":"21","author":"Lu","year":"2022","journal-title":"Mol Cancer"},{"issue":"3","key":"10.1016\/j.bcp.2025.116762_b0230","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","volume":"33","author":"Hayden","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bcp.2025.116762_b0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2022.100929","article-title":"Current state and next-generation CAR-T cells in multiple myeloma","volume":"54","author":"Manier","year":"2022","journal-title":"Blood Rev"},{"key":"10.1016\/j.bcp.2025.116762_b0240","article-title":"CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"issue":"16","key":"10.1016\/j.bcp.2025.116762_b0245","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22168996","article-title":"CAR T-Cell Therapy in Hematological Malignancies","volume":"22","author":"Haslauer","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"7","key":"10.1016\/j.bcp.2025.116762_b0250","doi-asserted-by":"crossref","first-page":"7844","DOI":"10.1002\/cam4.5551","article-title":"Chimeric antigen receptor T (CAR-T) cells: Novel cell therapy for hematological malignancies","volume":"12","author":"Abbasi","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.bcp.2025.116762_b0255","article-title":"CAR-T cell therapy for hematological malignancies: Limitations and optimization strategies","volume":"13","author":"Huang","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.bcp.2025.116762_b0260","article-title":"Advances in acute myeloid leukemia","volume":"375","author":"Newell","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.bcp.2025.116762_b0265","doi-asserted-by":"crossref","unstructured":"E. Atilla, K. Benabdellah, The Black Hole: CAR T Cell Therapy in AML, Cancers (Basel) 15(10) (2023).","DOI":"10.3390\/cancers15102713"},{"issue":"4","key":"10.1016\/j.bcp.2025.116762_b0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2019.101104","article-title":"How close are we to CAR T-cell therapy for AML?","volume":"32","author":"Gill","year":"2019","journal-title":"Best Pract Res Clin Haematol"},{"issue":"5","key":"10.1016\/j.bcp.2025.116762_b0275","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14051241","article-title":"Emerging CAR T Cell Strategies for the Treatment of AML","volume":"14","author":"Vishwasrao","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bcp.2025.116762_b0280","doi-asserted-by":"crossref","unstructured":"S. Haubner, J. Mansilla-Soto, S. Nataraj, F. Kogel, Q. Chang, E. de Stanchina, et al., Cooperative CAR targeting to selectively eliminate AML and minimize escape, Cancer Cell 41(11) (2023) 1871-1891 e6.","DOI":"10.1016\/j.ccell.2023.09.010"},{"issue":"2","key":"10.1016\/j.bcp.2025.116762_b0285","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1053\/j.seminhematol.2018.08.008","article-title":"Will CAR T cell therapy have a role in AML?","volume":"56","author":"Cummins","year":"2019","journal-title":"Promises and Pitfalls, Semin Hematol"},{"issue":"1","key":"10.1016\/j.bcp.2025.116762_b0290","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13045-021-01062-w","article-title":"Emerging agents and regimens for AML","volume":"14","author":"Liu","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.bcp.2025.116762_b0295","doi-asserted-by":"crossref","DOI":"10.1080\/16078454.2023.2196482","article-title":"A review of treatment options employed in relapsed\/refractory AML","volume":"28","author":"Mohamed Jiffry","year":"2023","journal-title":"Hematology"},{"issue":"10","key":"10.1016\/j.bcp.2025.116762_b0300","doi-asserted-by":"crossref","DOI":"10.3390\/jpm11101003","article-title":"New Drugs Bringing New Challenges to AML: A Brief Review","volume":"11","author":"Yeoh","year":"2021","journal-title":"J Pers Med"},{"issue":"2","key":"10.1016\/j.bcp.2025.116762_b0305","first-page":"77","article-title":"Therapy related AML in a case of chronic lymphocytic leukemia","volume":"13","author":"Gajendra","year":"2023","journal-title":"Am J Blood Res"},{"issue":"13","key":"10.1016\/j.bcp.2025.116762_b0310","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1182\/blood-2012-10-462440","article-title":"Significance of FAB subclassification of \u201cacute myeloid leukemia, NOS\u201d in the 2008 WHO classification: analysis of 5848 newly diagnosed patients","volume":"121","author":"Walter","year":"2013","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bcp.2025.116762_b0315","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1182\/blood.V68.6.1355.1355","article-title":"Classifying acute leukemia by immunophenotyping: a combined FAB-immunologic classification of AML","volume":"68","author":"Neame","year":"1986","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bcp.2025.116762_b0320","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/cyto.b.21050","article-title":"Expression of immune inhibitory receptor ILT3 in acute myeloid leukemia with monocytic differentiation","volume":"84","author":"Dobrowolska","year":"2013","journal-title":"Cytometry B Clin Cytom"},{"key":"10.1016\/j.bcp.2025.116762_b0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2020.106480","article-title":"The association of leukocyte immunoglobulin-like receptor subfamily B-4 expression in acute myeloid leukemia and central nervous system involvement","volume":"100","author":"Bergstrom","year":"2021","journal-title":"Leuk Res"},{"issue":"2","key":"10.1016\/j.bcp.2025.116762_b0330","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.pathol.2018.11.002","article-title":"Apolipoprotein E in lipoprotein metabolism, health and cardiovascular disease","volume":"51","author":"Marais","year":"2019","journal-title":"Pathology"},{"key":"10.1016\/j.bcp.2025.116762_b0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2020.104809","article-title":"Beyond the CNS: The many peripheral roles of APOE","volume":"138","author":"Martinez-Martinez","year":"2020","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.bcp.2025.116762_b0340","first-page":"536","article-title":"Apoproteins E","volume":"10","author":"Getz","year":"2019","journal-title":"A-i, and SAA in Macrophage Pathobiology Related to Atherogenesis, Front Pharmacol"},{"issue":"3","key":"10.1016\/j.bcp.2025.116762_b0345","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/j.1365-2567.2004.01972.x","article-title":"Heterogeneous expression of apolipoprotein-E by human macrophages","volume":"113","author":"Tedla","year":"2004","journal-title":"Immunology"},{"issue":"3","key":"10.1016\/j.bcp.2025.116762_b0350","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/sj.leu.2403250","article-title":"CD87 (urokinase-type plasminogen activator receptor), function and pathology in hematological disorders: a review","volume":"18","author":"Bene","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.bcp.2025.116762_b0355","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/7329072","article-title":"Protein Arginine Methyltransferase 5 Promotes the Migration of AML Cells by Regulating the Expression of Leukocyte Immunoglobulin-Like Receptor B4","volume":"2021","author":"Zhao","year":"2021","journal-title":"Biomed Res Int"},{"issue":"11","key":"10.1016\/j.bcp.2025.116762_b0360","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1158\/1535-7163.MCT-20-0407","article-title":"LILRB4-targeting Antibody-Drug Conjugates for the Treatment of Acute Myeloid Leukemia","volume":"19","author":"Anami","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bcp.2025.116762_b0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.bpc.2021.106746","article-title":"Biomimetic design of inhibitors of immune checkpoint LILRB4","volume":"282","author":"Chao","year":"2022","journal-title":"Biophys Chem"},{"issue":"10","key":"10.1016\/j.bcp.2025.116762_b0370","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1016\/j.ymthe.2018.08.001","article-title":"A Novel Anti-LILRB4 CAR-T Cell for the Treatment of Monocytic AML","volume":"26","author":"John","year":"2018","journal-title":"Mol Ther"},{"issue":"18","key":"10.1016\/j.bcp.2025.116762_b0375","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1182\/blood-2017-03-775858","article-title":"Ectopic ILT3 controls BCR-dependent activation of Akt in B-cell chronic lymphocytic leukemia","volume":"130","author":"Zurli","year":"2017","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.bcp.2025.116762_b0380","doi-asserted-by":"crossref","first-page":"4148","DOI":"10.1182\/bloodadvances.2022009477","article-title":"Identification of evolutionary mechanisms of myelomatous effusion by single-cell RNA sequencing","volume":"7","author":"Sun","year":"2023","journal-title":"Blood Adv"},{"issue":"18","key":"10.1016\/j.bcp.2025.116762_b0385","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.bcp.2025.116762_b0390","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41575-022-00591-0","article-title":"The immune microenvironment in gastric adenocarcinoma","volume":"19","author":"Zavros","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.bcp.2025.116762_b0395","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.canlet.2019.11.009","article-title":"Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy","volume":"470","author":"Lei","year":"2020","journal-title":"Cancer Lett"},{"issue":"4","key":"10.1016\/j.bcp.2025.116762_b0400","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1152\/physrev.00042.2019","article-title":"Microenvironmental Determinants of Pancreatic Cancer","volume":"100","author":"Hessmann","year":"2020","journal-title":"Physiol Rev"},{"key":"10.1016\/j.bcp.2025.116762_b0405","article-title":"Interplay between Solid Tumors and Tumor Microenvironment","volume":"13","author":"Kim","year":"2022","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.bcp.2025.116762_b0410","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/s41419-023-06110-6","article-title":"Stromal cells in the tumor microenvironment: accomplices of tumor progression?","volume":"14","author":"Zhao","year":"2023","journal-title":"Cell Death Dis"},{"issue":"4","key":"10.1016\/j.bcp.2025.116762_b0415","doi-asserted-by":"crossref","first-page":"910","DOI":"10.3892\/mmr.2012.744","article-title":"Expression of immunoglobulin-like transcript (ILT)2 and ILT3 in human gastric cancer and its clinical significance","volume":"5","author":"Zhang","year":"2012","journal-title":"Mol Med Rep"},{"issue":"10","key":"10.1016\/j.bcp.2025.116762_b0420","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1016\/j.prp.2018.07.026","article-title":"Expression of ILT3 predicts poor prognosis and is inversely associated with infiltration of CD45RO+ T cells in patients with colorectal cancer","volume":"214","author":"Liu","year":"2018","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.bcp.2025.116762_b0425","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.canlet.2020.10.048","article-title":"ILT3 promotes tumor cell motility and angiogenesis in non-small cell lung cancer","volume":"501","author":"Li","year":"2021","journal-title":"Cancer Lett"},{"issue":"11","key":"10.1016\/j.bcp.2025.116762_b0430","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1158\/2326-6066.CIR-21-0240","article-title":"The Fibronectin-ILT3 Interaction Functions as a Stromal Checkpoint that Suppresses Myeloid Cells","volume":"9","author":"Paavola","year":"2021","journal-title":"Cancer Immunol Res"},{"issue":"6","key":"10.1016\/j.bcp.2025.116762_b0435","first-page":"697","article-title":"Pancreas cancer and the role of soluble immunoglobulin-like transcript 3 (ILT3)","volume":"8","author":"Cortesini","year":"2007","journal-title":"JOP"},{"issue":"7","key":"10.1016\/j.bcp.2025.116762_b0440","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1014242","article-title":"Immunoglobulin-like transcript 3 is expressed by myeloid-derived suppressor cells and correlates with survival in patients with non-small cell lung cancer","volume":"4","author":"de Goeje","year":"2015","journal-title":"Oncoimmunology"},{"issue":"7","key":"10.1016\/j.bcp.2025.116762_b0445","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201811","article-title":"LILRB4 suppresses immunity in solid tumors and is a potential target for immunotherapy","volume":"218","author":"Sharma","year":"2021","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.bcp.2025.116762_b0450","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/eji.200636498","article-title":"IL-10 inhibits endothelium-dependent T cell costimulation by up-regulation of ILT3\/4 in human vascular endothelial cells","volume":"37","author":"Gleissner","year":"2007","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.bcp.2025.116762_b0455","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.molimm.2021.05.011","article-title":"Expression of leukocyte immunoglobulin-like receptor subfamily B expression on immune cells in hepatocellular carcinoma","volume":"136","author":"Fan","year":"2021","journal-title":"Mol Immunol"},{"issue":"21","key":"10.1016\/j.bcp.2025.116762_b0460","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1111\/1759-7714.14991","article-title":"Prognostic impact of LILRB4 expression on tumor-infiltrating cells in resected non-small cell lung cancer","volume":"14","author":"Kumata","year":"2023","journal-title":"Thorac Cancer"},{"issue":"1","key":"10.1016\/j.bcp.2025.116762_b0465","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2060907","article-title":"LILRB4 promotes tumor metastasis by regulating MDSCs and inhibiting miR-1 family miRNAs","volume":"11","author":"Su","year":"2022","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.bcp.2025.116762_b0470","doi-asserted-by":"crossref","unstructured":"R. Su, L. Dong, Y. Li, M. Gao, L. Han, M. Wunderlich, et al., Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion, Cancer Cell 38(1) (2020) 79-96 e11.","DOI":"10.1016\/j.ccell.2020.04.017"},{"issue":"4","key":"10.1016\/j.bcp.2025.116762_b0475","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1158\/1541-7786.MCR-20-0622","article-title":"ILT3 (LILRB4) Promotes the Immunosuppressive Function of Tumor-Educated Human Monocytic Myeloid-Derived Suppressor Cells","volume":"19","author":"Singh","year":"2021","journal-title":"Mol Cancer Res"},{"issue":"4","key":"10.1016\/j.bcp.2025.116762_b0480","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/joim.12395","article-title":"Human autoimmune diseases: a comprehensive update","volume":"278","author":"Wang","year":"2015","journal-title":"J Intern Med"},{"key":"10.1016\/j.bcp.2025.116762_b0485","doi-asserted-by":"crossref","DOI":"10.1016\/j.coi.2022.102266","article-title":"The increasing prevalence of autoimmunity and autoimmune diseases: an urgent call to action for improved understanding, diagnosis, treatment, and prevention","volume":"80","author":"Miller","year":"2023","journal-title":"Curr Opin Immunol"},{"issue":"2","key":"10.1016\/j.bcp.2025.116762_b0490","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103496","article-title":"Machine learning application in autoimmune diseases: State of art and future prospectives","volume":"23","author":"Danieli","year":"2024","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.bcp.2025.116762_b0495","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00134-023-07266-7","article-title":"Diagnosis and management of autoimmune diseases in the ICU","volume":"50","author":"Dumas","year":"2024","journal-title":"Intensive Care Med"},{"issue":"9","key":"10.1016\/j.bcp.2025.116762_b0500","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103142","article-title":"Alarmins in autoimmune diseases","volume":"21","author":"Danieli","year":"2022","journal-title":"Autoimmun Rev"},{"issue":"8","key":"10.1016\/j.bcp.2025.116762_b0505","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s00018-022-04433-9","article-title":"Age-associated B cells in autoimmune diseases","volume":"79","author":"Mouat","year":"2022","journal-title":"Cell Mol Life Sci"},{"issue":"11","key":"10.1016\/j.bcp.2025.116762_b0510","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41584-022-00841-0","article-title":"Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases","volume":"18","author":"Tison","year":"2022","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"10.1016\/j.bcp.2025.116762_b0515","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102743","article-title":"An updated advance of autoantibodies in autoimmune diseases","volume":"20","author":"Xiao","year":"2021","journal-title":"Autoimmun Rev"},{"issue":"5","key":"10.1016\/j.bcp.2025.116762_b0520","first-page":"997","article-title":"Systemic lupus erythematosus: one year in review 2023","volume":"41","author":"Zucchi","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.bcp.2025.116762_b0525","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1223322","article-title":"Clinical features of myasthenia gravis with neurological and systemic autoimmune diseases","volume":"14","author":"Zhu","year":"2023","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.bcp.2025.116762_b0530","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103312","article-title":"Treatment of autoimmunity: The impact of disease-modifying therapies in multiple sclerosis and comorbid autoimmune disorders","volume":"22","author":"Konen","year":"2023","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.bcp.2025.116762_b0535","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.108647","article-title":"An overview of immune checkpoint therapy in autoimmune diseases","volume":"107","author":"Mohammadi","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.bcp.2025.116762_b0540","article-title":"Macrophage: Key player in the pathogenesis of autoimmune diseases","volume":"14","author":"Yang","year":"2023","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.bcp.2025.116762_b0545","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103260","article-title":"Exosomes as biomarkers and therapeutic delivery for autoimmune diseases: Opportunities and challenges","volume":"22","author":"Fang","year":"2023","journal-title":"Autoimmun Rev"},{"issue":"6","key":"10.1016\/j.bcp.2025.116762_b0550","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103326","article-title":"Global burden and cross-country inequalities in autoimmune diseases from 1990 to 2019","volume":"22","author":"Cao","year":"2023","journal-title":"Autoimmun Rev"},{"issue":"10391","key":"10.1016\/j.bcp.2025.116762_b0555","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1016\/S0140-6736(23)00457-9","article-title":"Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK","volume":"401","author":"Conrad","year":"2023","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.bcp.2025.116762_b0560","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103407","article-title":"A global assessment of incidence trends of autoimmune diseases from 1990 to 2019 and predicted changes to 2040","volume":"22","author":"Li","year":"2023","journal-title":"Autoimmun Rev"},{"issue":"12","key":"10.1016\/j.bcp.2025.116762_b0565","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1093\/intimm\/dxw044","article-title":"Tolerogenic immunoreceptor ILT3\/LILRB4 paradoxically marks pathogenic auto-antibody-producing plasmablasts and plasma cells in non-treated SLE","volume":"28","author":"Inui","year":"2016","journal-title":"Int Immunol"},{"issue":"6","key":"10.1016\/j.bcp.2025.116762_b0570","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/intimm\/dxz017","article-title":"Gp49B is a pathogenic marker for auto-antibody-producing plasma cells in lupus-prone BXSB\/Yaa mice","volume":"31","author":"Wong","year":"2019","journal-title":"Int Immunol"},{"issue":"4","key":"10.1016\/j.bcp.2025.116762_b0575","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1136\/annrheumdis-2012-202024","article-title":"Functional genetic polymorphisms in ILT3 are associated with decreased surface expression on dendritic cells and increased serum cytokines in lupus patients","volume":"72","author":"Jensen","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.bcp.2025.116762_b0580","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/intimm\/dxab028","article-title":"Blockade of checkpoint ILT3\/LILRB4\/gp49B binding to fibronectin ameliorates autoimmune disease in BXSB\/Yaa mice","volume":"33","author":"Su","year":"2021","journal-title":"Int Immunol"},{"issue":"10","key":"10.1016\/j.bcp.2025.116762_b0585","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.bcp.2025.116762_b0590","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1038\/s41423-020-0472-1","article-title":"Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus","volume":"18","author":"Jin","year":"2021","journal-title":"Cell Mol Immunol"},{"issue":"12","key":"10.1016\/j.bcp.2025.116762_b0595","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41584-022-00865-6","article-title":"CAR T cells induce drug-free SLE remission","volume":"18","author":"Phillips","year":"2022","journal-title":"Nat Rev Rheumatol"},{"issue":"8","key":"10.1016\/j.bcp.2025.116762_b0600","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up","volume":"390","author":"Muller","year":"2024","journal-title":"N Engl J Med"},{"issue":"10416","key":"10.1016\/j.bcp.2025.116762_b0605","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/S0140-6736(23)01126-1","article-title":"CAR T-cell therapy in autoimmune diseases","volume":"402","author":"Schett","year":"2023","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.bcp.2025.116762_b0610","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1474-4422(22)00289-7","article-title":"Multiple sclerosis progression: time for a new mechanism-driven framework","volume":"22","author":"Kuhlmann","year":"2023","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1016\/j.bcp.2025.116762_b0615","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1212\/CON.0000000000001136","article-title":"Epidemiology and Pathophysiology of Multiple Sclerosis","volume":"28","author":"Ward","year":"2022","journal-title":"Continuum (minneap Minn)"},{"issue":"1","key":"10.1016\/j.bcp.2025.116762_b0620","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2217\/nmt-2021-0058","article-title":"Updates and advances in multiple sclerosis neurotherapeutics","volume":"13","author":"Amin","year":"2023","journal-title":"Neurodegener Dis Manag"},{"issue":"4","key":"10.1016\/j.bcp.2025.116762_b0625","doi-asserted-by":"crossref","first-page":"199","DOI":"10.31128\/AJGP-07-21-6103","article-title":"Multiple sclerosis: Diagnosis, disease-modifying therapy and prognosis","volume":"51","author":"Travers","year":"2022","journal-title":"Aust J Gen Pract"},{"issue":"8","key":"10.1016\/j.bcp.2025.116762_b0630","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000037297","article-title":"Review of multiple sclerosis: Epidemiology, etiology, pathophysiology, and treatment","volume":"103","author":"Haki","year":"2024","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.bcp.2025.116762_b0635","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1177\/1352458509352794","article-title":"Immunoglobulin-like transcript 3, an inhibitor of T cell activation, is reduced on blood monocytes during multiple sclerosis relapses and is induced by interferon beta-1b","volume":"16","author":"Jensen","year":"2010","journal-title":"Mult Scler"},{"issue":"12","key":"10.1016\/j.bcp.2025.116762_b0640","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0115488","article-title":"Interferon beta and vitamin D synergize to induce immunoregulatory receptors on peripheral blood monocytes of multiple sclerosis patients","volume":"9","author":"Waschbisch","year":"2014","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.bcp.2025.116762_b0645","doi-asserted-by":"crossref","first-page":"554","DOI":"10.4049\/jimmunol.2000265","article-title":"Suppression of Experimental Autoimmune Encephalomyelitis by ILT3.Fc","volume":"206","author":"Xu","year":"2021","journal-title":"J Immunol"},{"key":"10.1016\/j.bcp.2025.116762_b0650","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173090","article-title":"Macrophage M1\/M2 polarization","volume":"877","author":"Yunna","year":"2020","journal-title":"Eur J Pharmacol"},{"issue":"9","key":"10.1016\/j.bcp.2025.116762_b0655","doi-asserted-by":"crossref","first-page":"6425","DOI":"10.1002\/jcp.26429","article-title":"Macrophage plasticity, polarization, and function in health and disease","volume":"233","author":"Shapouri-Moghaddam","year":"2018","journal-title":"J Cell Physiol"},{"issue":"13","key":"10.1016\/j.bcp.2025.116762_b0660","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22136995","article-title":"Macrophage Polarization States in the Tumor Microenvironment","volume":"22","author":"Boutilier","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bcp.2025.116762_b0665","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1146\/annurev-pathmechdis-012418-012718","article-title":"Diversity, Mechanisms, and Significance of Macrophage Plasticity","volume":"15","author":"Locati","year":"2020","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.bcp.2025.116762_b0670","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1146\/annurev-physiol-022516-034339","article-title":"Macrophage Polarization","volume":"79","author":"Murray","year":"2017","journal-title":"Annu Rev Physiol"},{"issue":"1","key":"10.1016\/j.bcp.2025.116762_b0675","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.emc.2021.08.007","article-title":"Overview of Allergy and Anaphylaxis","volume":"40","author":"Dribin","year":"2022","journal-title":"Emerg Med Clin North Am"},{"key":"10.1016\/j.bcp.2025.116762_b0680","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2022.101104","article-title":"Siglecs in allergy and asthma","volume":"90","author":"Bochner","year":"2023","journal-title":"Mol Aspects Med"},{"issue":"6","key":"10.1016\/j.bcp.2025.116762_b0685","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.anai.2023.08.609","article-title":"Consensus of an American College of Allergy, Asthma, and Immunology, American Academy of Allergy, Asthma, and Immunology, and American Thoracic Society workgroup on definition of clinical remission in asthma on treatment","volume":"131","author":"Blaiss","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"9","key":"10.1016\/j.bcp.2025.116762_b0690","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s11882-023-01098-7","article-title":"Podcasting in Clinical Allergy and Immunology: Our Experience and a Review of the Current Landscape","volume":"23","author":"Gupta","year":"2023","journal-title":"Curr Allergy Asthma Rep"},{"issue":"10","key":"10.1016\/j.bcp.2025.116762_b0695","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/imcb.12688","article-title":"A conversation on allergy: recognizing the past and looking to the future","volume":"101","author":"Melen","year":"2023","journal-title":"Immunol Cell Biol"},{"issue":"5","key":"10.1016\/j.bcp.2025.116762_b0700","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.jaip.2024.02.018","article-title":"An Ethical Framework for Allergy and Immunology","volume":"12","author":"Buckey","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.bcp.2025.116762_b0705","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1600-065X.2007.00522.x","article-title":"Inhibition of pathologic inflammation by leukocyte Ig-like receptor B4 and related inhibitory receptors","volume":"217","author":"Katz","year":"2007","journal-title":"Immunol Rev"},{"issue":"2","key":"10.1016\/j.bcp.2025.116762_b0710","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1084\/jem.194.2.227","article-title":"Increased severity of local and systemic anaphylactic reactions in gp49B1-deficient mice","volume":"194","author":"Daheshia","year":"2001","journal-title":"J Exp Med"},{"issue":"6","key":"10.1016\/j.bcp.2025.116762_b0715","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1189\/jlb.1106667","article-title":"Inhibitory receptor gp49B regulates eosinophil infiltration during allergic inflammation","volume":"82","author":"Norris","year":"2007","journal-title":"J Leukoc Biol"},{"issue":"1","key":"10.1016\/j.bcp.2025.116762_b0720","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41572-023-00438-1","article-title":"Acute graft-versus-host disease","volume":"9","author":"Malard","year":"2023","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"10.1016\/j.bcp.2025.116762_b0725","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/S2352-3026(23)00342-3","article-title":"Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation","volume":"11","author":"Penack","year":"2024","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.bcp.2025.116762_b0730","first-page":"1","article-title":"Chronic graft-versus-host disease","volume":"90","author":"Baumrin","year":"2024","journal-title":"Part i: Epidemiology, Pathogenesis, and Clinical Manifestations, J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.bcp.2025.116762_b0735","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s11912-023-01363-y","article-title":"Graft-Versus-Host Disease: an Update on Functional Implications and Rehabilitation Interventions","volume":"25","author":"Brothers","year":"2023","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"10.1016\/j.bcp.2025.116762_b0740","first-page":"19","article-title":"Chronic graft-versus-host disease","volume":"90","author":"Baumrin","year":"2024","journal-title":"Part II: Disease Activity Grading and Therapeutic Management, J Am Acad Dermatol"},{"issue":"9","key":"10.1016\/j.bcp.2025.116762_b0745","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/14728222.2021.1992383","article-title":"New therapeutic targets and biomarkers for acute graft-versus-host disease (GVHD)","volume":"25","author":"Choe","year":"2021","journal-title":"Expert Opin Ther Targets"},{"issue":"8","key":"10.1016\/j.bcp.2025.116762_b0750","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1093\/oncolo\/oyac076","article-title":"Recent FDA Approvals in the Treatment of Graft-Versus-Host Disease","volume":"27","author":"Martini","year":"2022","journal-title":"Oncologist"},{"issue":"10","key":"10.1016\/j.bcp.2025.116762_b0755","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1200\/JCO.22.02256","article-title":"Novel Approaches to the Treatment of Chronic Graft-Versus-Host Disease","volume":"41","author":"Zeiser","year":"2023","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.bcp.2025.116762_b0760","doi-asserted-by":"crossref","first-page":"5088","DOI":"10.1182\/blood-2011-11-364091","article-title":"Dendritic cells and regulation of graft-versus-host disease and graft-versus-leukemia activity","volume":"119","author":"Stenger","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bcp.2025.116762_b0765","doi-asserted-by":"crossref","DOI":"10.1172\/JCI136774","article-title":"Graft-versus-host disease depletes plasmacytoid dendritic cell progenitors to impair tolerance induction","volume":"131","author":"Tian","year":"2021","journal-title":"J Clin Invest"},{"issue":"564","key":"10.1016\/j.bcp.2025.116762_b0770","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aay4799","article-title":"ICOSL(+) plasmacytoid dendritic cells as inducer of graft-versus-host disease, responsive to a dual ICOS\/CD28 antagonist","volume":"12","author":"Adom","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.bcp.2025.116762_b0775","doi-asserted-by":"crossref","DOI":"10.3791\/60083","article-title":"Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease","author":"Nguyen","year":"2020","journal-title":"J vis Exp (157)"},{"issue":"3","key":"10.1016\/j.bcp.2025.116762_b0780","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/ni760","article-title":"Tolerization of dendritic cells by T(S) cells: the crucial role of inhibitory receptors ILT3 and ILT4","volume":"3","author":"Chang","year":"2002","journal-title":"Nat Immunol"},{"issue":"9","key":"10.1016\/j.bcp.2025.116762_b0785","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.humimm.2009.06.001","article-title":"Suppression of xenogeneic graft-versus-host disease by treatment with immunoglobulin-like transcript 3-Fc","volume":"70","author":"Vlad","year":"2009","journal-title":"Hum Immunol"},{"issue":"3","key":"10.1016\/j.bcp.2025.116762_b0790","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24032995","article-title":"Endometrial Microbiota and Immune Tolerance in Pregnancy","volume":"24","author":"Inversetti","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.bcp.2025.116762_b0795","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2021.105205","article-title":"The flawless immune tolerance of pregnancy","volume":"88","author":"Genebrier","year":"2021","journal-title":"Joint Bone Spine"},{"issue":"4","key":"10.1016\/j.bcp.2025.116762_b0800","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1080\/08820139.2021.1909061","article-title":"Fetomaternal Immune Tolerance: Crucial Mechanisms of Tolerance for Successful Pregnancy in Humans","volume":"51","author":"Yousefzadeh","year":"2022","journal-title":"Immunol Invest"},{"issue":"2","key":"10.1016\/j.bcp.2025.116762_b0805","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/08830185.2020.1723961","article-title":"Balancing immune tolerance and immune responses","volume":"39","author":"Kumar","year":"2020","journal-title":"Int Rev Immunol"},{"issue":"12","key":"10.1016\/j.bcp.2025.116762_b0810","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1007\/s43032-021-00599-y","article-title":"The Role of Immune Cells in Recurrent Spontaneous Abortion","volume":"28","author":"Li","year":"2021","journal-title":"Reprod Sci"},{"issue":"2","key":"10.1016\/j.bcp.2025.116762_b0815","doi-asserted-by":"crossref","first-page":"781","DOI":"10.4049\/jimmunol.166.2.781","article-title":"Uterine macrophages express the gp49B inhibitory receptor in midgestation","volume":"166","author":"Matsumoto","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.bcp.2025.116762_b0820","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.3389\/fimmu.2017.01013","article-title":"Decidual Macrophage Functional Polarization during Abnormal Pregnancy due to Toxoplasma gondii: Role for LILRB4","volume":"8","author":"Li","year":"2017","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.bcp.2025.116762_b0825","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1186\/s13071-023-05856-4","article-title":"LILRB4 regulates the function of decidual MDSCs via the SHP-2\/STAT6 pathway during Toxoplasma gondii infection","volume":"16","author":"Li","year":"2023","journal-title":"Parasit Vectors"},{"key":"10.1016\/j.bcp.2025.116762_b0830","doi-asserted-by":"crossref","first-page":"588","DOI":"10.3389\/fmicb.2018.00588","article-title":"LILRB4 Decrease on uDCs Exacerbate Abnormal Pregnancy Outcomes Following Toxoplasma gondii Infection","volume":"9","author":"Zhan","year":"2018","journal-title":"Front Microbiol"},{"issue":"1","key":"10.1016\/j.bcp.2025.116762_b0835","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.bbrc.2018.11.137","article-title":"Leukocyte immunoglobulin-like receptor B4 (LILRB4) negatively mediates the pathological cardiac hypertrophy by suppressing fibrosis, inflammation and apoptosis via the activation of NF-kappaB signaling","volume":"509","author":"Li","year":"2019","journal-title":"Biochem Biophys Res Commun"},{"issue":"17","key":"10.1016\/j.bcp.2025.116762_b0840","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1042\/CS20170198","article-title":"LILRB4 deficiency aggravates the development of atherosclerosis and plaque instability by increasing the macrophage inflammatory response via NF-kappaB signaling","volume":"131","author":"Jiang","year":"2017","journal-title":"Clin Sci (lond)"},{"issue":"6","key":"10.1016\/j.bcp.2025.116762_b0845","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20181888","article-title":"Leukocyte immunoglobulin-like receptor B4 deficiency exacerbates acute lung injury via NF-kappaB signaling in bone marrow-derived macrophages","volume":"39","author":"Qiu","year":"2019","journal-title":"Biosci Rep"},{"issue":"2","key":"10.1016\/j.bcp.2025.116762_b0850","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1053\/j.gastro.2010.04.006","article-title":"Paired immunoglobulin-like receptor B (PIR-B) negatively regulates macrophage activation in experimental colitis","volume":"139","author":"Munitz","year":"2010","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.bcp.2025.116762_b0855","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/s41392-020-00312-6","article-title":"Targeting NF-kappaB pathway for the therapy of diseases: mechanism and clinical study","volume":"5","author":"Yu","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.bcp.2025.116762_b0860","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.716469","article-title":"NF-kappaB: At the Borders of Autoimmunity and Inflammation","volume":"12","author":"Barnabei","year":"2021","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.bcp.2025.116762_b0865","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/nri.2017.52","article-title":"The non-canonical NF-kappaB pathway in immunity and inflammation","volume":"17","author":"Sun","year":"2017","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"10.1016\/j.bcp.2025.116762_b0870","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s00109-020-01896-w","article-title":"Leukocyte immunoglobulin-like receptor B4 protects against cardiac hypertrophy via SHP-2-dependent inhibition of the NF-kappaB pathway","volume":"98","author":"Zhou","year":"2020","journal-title":"J Mol Med (berl)"},{"issue":"4","key":"10.1016\/j.bcp.2025.116762_b0875","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/hep.29633","article-title":"Hepatic leukocyte immunoglobulin-like receptor B4 (LILRB4) attenuates nonalcoholic fatty liver disease via SHP1-TRAF6 pathway","volume":"67","author":"Lu","year":"2018","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.bcp.2025.116762_b0880","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s12931-021-01828-3","article-title":"Upregulation of leukocyte immunoglobulin-like receptor B4 on interstitial macrophages in COPD; their possible protective role against emphysema formation","volume":"22","author":"Mitsune","year":"2021","journal-title":"Respir Res"},{"issue":"4","key":"10.1016\/j.bcp.2025.116762_b0885","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/INF.0000000000002259","article-title":"Augmented ILT3\/LILRB4 Expression of Peripheral Blood Antibody Secreting Cells in the Acute Phase of Kawasaki Disease","volume":"38","author":"Sugahara-Tobinai","year":"2019","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.bcp.2025.116762_b0890","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1471-2172-10-56","volume":"10","author":"Brown","year":"2009","journal-title":"BMC Immunol"},{"key":"10.1016\/j.bcp.2025.116762_b0895","first-page":"1","article-title":"Introduction to the Immune System","volume":"2019","author":"McComb","year":"2024","journal-title":"Methods Mol Biol"},{"issue":"44","key":"10.1016\/j.bcp.2025.116762_b0900","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2308511120","article-title":"The total mass, number, and distribution of immune cells in the human body","volume":"120","author":"Sender","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"10.1016\/j.bcp.2025.116762_b0905","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41571-020-0413-z","article-title":"Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors","volume":"17","author":"Galluzzi","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.bcp.2025.116762_b0910","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.drudis.2019.11.003","article-title":"Immune checkpoint inhibitors: a promising anticancer therapy","volume":"25","author":"Singh","year":"2020","journal-title":"Drug Discov Today"},{"issue":"5","key":"10.1016\/j.bcp.2025.116762_b0915","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2022.188771","article-title":"CD47: Beyond an immune checkpoint in cancer treatment","volume":"1877","author":"Bian","year":"2022","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"5","key":"10.1016\/j.bcp.2025.116762_b0920","doi-asserted-by":"crossref","DOI":"10.1093\/molehr\/gaac010","article-title":"Macrophage-associated immune checkpoint CD47 blocking ameliorates endometriosis","volume":"28","author":"Li","year":"2022","journal-title":"Mol Hum Reprod"},{"key":"10.1016\/j.bcp.2025.116762_b0925","doi-asserted-by":"crossref","DOI":"10.1007\/s00415-024-12367-4","article-title":"Bispecific BCMA\/CD19 targeted CAR-T cell therapy forces sustained disappearance of symptoms and anti-acetylcholine receptor antibodies in refractory myasthenia gravis: a case report","author":"Zhang","year":"2024","journal-title":"J Neurol"},{"issue":"3","key":"10.1016\/j.bcp.2025.116762_b0930","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.151420","article-title":"NK cells require immune checkpoint receptor LILRB4\/gp49B to control neurotropic Zika virus infections in mice","volume":"7","author":"Lee","year":"2022","journal-title":"JCI Insight"},{"issue":"4","key":"10.1016\/j.bcp.2025.116762_b0935","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/all.12350","article-title":"International Consensus on drug allergy","volume":"69","author":"Demoly","year":"2014","journal-title":"Allergy"},{"issue":"2","key":"10.1016\/j.bcp.2025.116762_b0940","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.iac.2022.01.001","article-title":"Pediatric Drug Allergy","volume":"42","author":"Prosty","year":"2022","journal-title":"Immunol Allergy Clin North Am"},{"issue":"4","key":"10.1016\/j.bcp.2025.116762_b0945","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/ACI.0000000000000651","article-title":"The economics of drug allergy","volume":"20","author":"Mattingly","year":"2020","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.bcp.2025.116762_b0950","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.863414","article-title":"Editorial: The Immunology of Adverse Drug Reactions","volume":"13","author":"Illing","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.bcp.2025.116762_b0955","doi-asserted-by":"crossref","unstructured":"P. Joint Task Force on Practice, A. American Academy of Allergy, Immunology, A. American College of Allergy, Immunology, A. Joint Council of Allergy, et al., Drug allergy: an updated practice parameter, Ann Allergy Asthma Immunol 105(4) (2010) 259-273.","DOI":"10.1016\/j.anai.2010.08.002"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225000243?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225000243?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:33:23Z","timestamp":1777401203000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295225000243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":191,"alternative-id":["S0006295225000243"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2025.116762","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"LILRB4 as a novel immunotherapeutic target for multiple diseases","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2025.116762","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116762"}}